Management of Hot Flashes in Women Without a Uterus

First-Line Treatment

The National Comprehensive Cancer Network recommends estrogen-alone therapy as the most effective treatment for hot flashes in women without a uterus, with a reduction in symptoms of 80-90% 1, 2, 3
Estrogen alone (without progestin) is appropriate for women without a uterus, as it avoids the risks associated with combined estrogen-progestin therapy 2, 3
Transdermal formulations are preferred over oral due to lower rates of venous thromboembolism and stroke 1

A history of hormonally mediated cancers is a contraindication for estrogen therapy, as recommended by the National Comprehensive Cancer Network 1

The National Comprehensive Cancer Network suggests that SSRIs/SNRIs, such as venlafaxine and paroxetine, have shown efficacy for hot flashes, with a reduction in hot flash score of 37-61% compared to 27% with placebo 4, 5, 6
Venlafaxine (SNRI) can be started at 37.5 mg/day and may be increased to 75 mg if needed, with side effects including dry mouth, decreased appetite, nausea, and constipation 6
Paroxetine (SSRI) can be used at 10-12.5 mg/day, with a reduction in hot flash composite score of 62-65%, but should be used with caution in patients taking tamoxifen due to CYP2D6 inhibition 5, 6
Gabapentin, an anticonvulsant, can be used at 900 mg/day (in divided doses) to reduce hot flash severity by 46% at 8 weeks, with side effects including somnolence and fatigue 4, 6

Acupuncture and cognitive behavioral therapy can be effective in reducing hot flashes, with several studies showing effectiveness comparable to medication 7
Lifestyle modifications, such as weight loss if overweight, smoking cessation, and limiting alcohol, can also help reduce hot flashes 7

The National Comprehensive Cancer Network recommends that treatment should be tailored based on the presence of contraindications, such as a history of hormonally mediated cancers 1
Using combined estrogen-progestin therapy in women without a uterus is unnecessary and increases risks, as stated by the National Comprehensive Cancer Network 1, 2
Using custom compounded bioidentical hormones is not recommended due to a lack of data supporting safety and efficacy claims, as stated by the National Comprehensive Cancer Network 1
Paroxetine should not be used in women also taking tamoxifen, as it may reduce tamoxifen's effectiveness, as recommended by the National Comprehensive Cancer Network 4
SSRIs/SNRIs should not be abruptly discontinued, but rather tapered to minimize withdrawal symptoms, as recommended by the Annals of Oncology 5

The U.S. Preventive Services Task Force recommends against using hormone therapy for primary prevention of chronic conditions, due to potential risks such as increased risk of stroke, venous thromboembolism, and gallbladder disease 8, 9
For women without a uterus, estrogen-alone therapy may have some benefits beyond symptom relief, including reduced risk of fractures and a small reduction in risk of invasive breast cancer 8, 9

Non-hormonal medications that can help with hot flashes include SNRIs like venlafaxine (37.5-75mg/day) and SSRIs like paroxetine (10-12.5mg/day), with lifestyle modifications such as environmental modifications (cool rooms, dressing in layers) also being effective 10

Women without a uterus should use estrogen-alone therapy, which avoids the additional risks associated with combined therapy, as recommended by the American College of Physicians, based on evidence from the Annals of Internal Medicine 8